University Medical Center Freiburg, Department of Hematology/Oncology, Hugstetter Strasse 55, D-79106, Freiburg, Germany.
Immunotherapy. 2009 Jan;1(1):63-72. doi: 10.2217/1750743X.1.1.63.
Vaccination with tumor antigen-loaded dendritic cells has been one of the most frequently applied immunotherapeutic strategies in prostate cancer. Immunological effects have been observed in a majority of patients, while clinical effects have been modest and transient. Advances in the understanding of the interplay between cancer and the immune system have generated new concepts in tumor immunology and immunotherapy that might aid in the improvement of vaccine effectiveness. The combination of immunotherapy with conventional treatment modalities and targeting of immunosuppressive mechanisms has demonstrated improved immunological and clinical results that warrant further investigation.
用肿瘤抗原负载的树突状细胞进行免疫接种是前列腺癌中最常应用的免疫治疗策略之一。大多数患者可观察到免疫效应，而临床疗效则较为温和且短暂。对癌症与免疫系统相互作用的认识的提高为肿瘤免疫学和免疫治疗带来了新的概念，这些概念可能有助于提高疫苗的效果。免疫疗法与传统治疗方式的联合应用以及免疫抑制机制的靶向治疗已经显示出改善免疫和临床结果的潜力，值得进一步研究。
